Hepatobiliary disorders associated with TNF-α inhibitors: a pharmacovigilance analysis of FAERS and JADER

The robust signal between adalimumab and hepatobiliary adverse events was observed in our study. Male sex and skin and subcutaneous tissue disorders were regarded as consistent independent risk factors. The factors of drug dose, body weight, and additional comorbidity clusters could also require attention in clinics because these factors were obviously observed in certain single databases.